10,833 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by USA Financial Formulas

USA Financial Formulas bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 10,833 shares of the life sciences company’s stock, valued at approximately $1,448,000. Illumina comprises approximately 0.2% of USA Financial Formulas’ portfolio, making the stock its 17th biggest position.

Several other institutional investors have also modified their holdings of ILMN. Versant Capital Management Inc raised its position in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV boosted its position in shares of Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Illumina during the second quarter worth about $61,000. Finally, Private Trust Co. NA grew its stake in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ILMN shares. Leerink Partners boosted their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Piper Sandler cut their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, UBS Group raised their price objective on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $136.19 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business has a 50-day moving average of $140.55 and a two-hundred day moving average of $133.10. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 earnings per share. On average, analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.